Akums Drugs and Pharmaceuticals Limited — PPTs, 09-11-2024: Investor Presentation

Akums Drugs and Pharmaceuticals Limited has released its investor presentation, detailing Q2 FY24 financial results. Adjusted EBITDA fell to ₹1,347 million despite improved gross margins at 42.3%. Adjusted PAT rose to ₹667 million, leading to a consolidated cash surplus of ₹3,406 million. The Company continues to face challenges in demand but remains focused on strengthening its market position and expanding its capabilities in the CDMO sector, which accounts for 77% of its revenue.